NATIONAL INSTITUTES OF HEALTH ISSUES NOTICE: GOVERNMENT OWNED INVENTION AVAILABLE FOR LICENSE: NUCLEOPHOSMIN 1 (NPM1) MUTATION-SPECIFIC T CELL RECEPTORS FOR TARGETED TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

WASHINGTON, July 24 -- National Institutes of Health has issued a notice called: Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML).

The notice was published in the Federal Register on July 24 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.

Summary: The NCI seeks research co-development partners or licensees for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of AML.

For more information, contact Inquiries related to this license opportunity should be directed to: Abritee Dhal, Ph.D, Technology Transfer Manager, NCI, Technology Transfer Center, Email: abritee.dh...